MycoLogics, Inc. Moves Closer Towards the Discovery of an Apergillus fumigatus Vaccine
MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to derive a novel vaccine against Aspergillus fumigatus
DENVER, CO (PRWEB) March 14, 2004--MycoLogics, Inc., an innovative
biotechnology company specializing in the development of novel antifungal drugs
and therapeutic and prophylactic vaccines against human fungal and parasitic
pathogens, today announced award of a Phase I SBIR grant by the Department of
Health and Human Services to derive a novel vaccine against Aspergillus
fumigatus, a ubiquitous spore-bearing fungus that causes multiple diseases in
humans. These diseases include allergic asthma, aspergillomas, and invasive
pulmonary disease of those with predisposing underlying
conditions.
Although aspergillosis-related hospitalizations account for a
small percentage of hospitalizations in the United States, patients hospitalized
with the condition have lengthy hospital stays and high mortality rates. The
high mortality rates, in some instances over 85%, are due in part to the lack of
sensitive diagnostic tests, as well as the lack of effective anti-fungal
therapeutics.
MycoLogics, Inc. is utilizing a vaccine delivery system
that is novel, very low in cost, highly flexible, and able to accommodate
potential cocktails; this a possibility not readily available to other current
vaccine projects. Collaboratoring on the project is the California Institute for
Medical Research.
“In certain patient populations mortality of
aspergillosis approaches 85%, a vaccine that increases immune response, even in
immunocompromised individuals, will be of significant benefit. This Phase I SBIR
grant will allow us to begin the development of a vaccine to treat or prevent
this very dangerous fungal infection,” said Dr. Claude P. Selitrennikoff, Ph.D.,
President and Chief Executive Officer of MycoLogics, Inc.
About
MycoLogics, Inc.
MycoLogics, Inc. is an innovative biotechnology company
specializing in the development of novel antifungal drugs and therapeutic and
prophylactic vaccines against human fungal and parasitic pathogens, the
discovery and isolation of novel antifungal compounds for therapeutic use, and
the development of novel high throughput assays that target components of fungal
cell walls. MycoLogics, Inc. is headquartered in Aurora, CO at the Fitzsimmons
Colorado Bioscience Park. For more information please visit www.mycologics.com.
CONTACT INFORMATION:
Dr. Claude
P. Selitrennikoff, Ph.D.
President and CEO
MycoLogics, Inc.
Colorado
Bioscience Park
12635 East Montview Blvd., Suite 131
Aurora, CO
80010
Tel: (303) 724-1250
Fax: (303) 724-0861
e-mail protected from
spam bots
# # #
Source : http://www.prweb.com/releases/2004/3/prweb111024.htm